Grifols (NASDAQ:GRFS) Posts Quarterly Earnings Results, Misses Estimates By $0.14 EPS

Grifols (NASDAQ:GRFS) announced its quarterly earnings data on Thursday. The biotechnology company reported $0.15 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.14), FiscalAI reports.

Here are the key takeaways from Grifols’ conference call:

• Grifols generated EUR 468 million free cash flow in FY‑2025 (pre‑M&A/pre‑dividends), up >€200m year‑over‑year, and guided 2026 free cash flow to EUR 500–575 million.
• Management is deliberately prioritizing profitability and cash generation over top‑line growth in 2026, targeting an adjusted EBITDA margin of at least 25% and adjusted EBITDA growth of 5–9% on a constant‑currency basis.
• The immunoglobulin franchise outperformed, with IG growth of 14.7% (IVIG +12%, SCIG +60%) driven by GAMUNEX‑C and XEMBIFY and deliberate share gains in the U.S.
• Strategic self‑sufficiency projects are a core value driver — EMA approval for Egyptian‑sourced plasma and the Canada partnership (raising IG self‑sufficiency to ~30% in 2025) are positioned to lower costs and support long‑term margin expansion.
• Albumin weakness in China, together with the IRA impact and certain accounting reclassifications, weighed on gross margins and EBITDA comparability, creating near‑term margin headwinds despite resilient free cash flow.

Grifols Price Performance

NASDAQ:GRFS traded down $0.29 during mid-day trading on Thursday, hitting $8.96. 2,324,217 shares of the company’s stock were exchanged, compared to its average volume of 444,352. The company has a current ratio of 2.48, a quick ratio of 0.93 and a debt-to-equity ratio of 1.20. Grifols has a one year low of $6.19 and a one year high of $11.14. The business has a fifty day moving average price of $9.22 and a 200 day moving average price of $9.37.

Hedge Funds Weigh In On Grifols

A number of hedge funds have recently bought and sold shares of the company. EverSource Wealth Advisors LLC increased its position in shares of Grifols by 127.4% during the second quarter. EverSource Wealth Advisors LLC now owns 8,219 shares of the biotechnology company’s stock valued at $74,000 after acquiring an additional 4,604 shares in the last quarter. Ameriprise Financial Inc. bought a new position in Grifols in the 2nd quarter valued at approximately $95,000. Ieq Capital LLC purchased a new stake in Grifols during the 4th quarter valued at $154,000. Creative Planning boosted its stake in Grifols by 15.0% during the 3rd quarter. Creative Planning now owns 16,414 shares of the biotechnology company’s stock valued at $163,000 after purchasing an additional 2,141 shares during the last quarter. Finally, Cerity Partners LLC increased its holdings in shares of Grifols by 6.3% in the 4th quarter. Cerity Partners LLC now owns 19,121 shares of the biotechnology company’s stock worth $179,000 after purchasing an additional 1,131 shares in the last quarter.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. JPMorgan Chase & Co. lowered their price objective on shares of Grifols from $10.30 to $10.00 and set a “neutral” rating on the stock in a report on Monday, December 8th. Zacks Research raised shares of Grifols from a “strong sell” rating to a “hold” rating in a report on Friday, February 6th. Wall Street Zen upgraded shares of Grifols from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 15th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Grifols in a research report on Thursday, January 22nd. Four investment analysts have rated the stock with a Hold rating, Based on data from MarketBeat, Grifols presently has an average rating of “Hold” and an average target price of $10.00.

Grifols Company Profile

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.